Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies

NCT05020678 is registered in ClinicalTrials.gov with Nkarta, Inc. as lead sponsor.

NCT NCT05020678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Lead sponsor
Nkarta, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 20, 2021
Completion date
December 31, 2038
Enrollment
150 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive lymphoma, b-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, indolent lymphoma, large b-cell lymphoma, large-cell lymphoma, lymphoma, non-hodgkin, mantle cell lymphoma, small lymphocytic lymphoma, waldenstrom macroglobulinemia